Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Myeloma
REVLIMID Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
July 5th, 2007
Celgene Corporation (NASDAQ:CELG) announced that REVLIMID (lenalidomide) has been granted full marketing authorization by the European Commission for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. This approval represents the first regulatory approval for Celgene in Europe, and REVLIMID represents the first breakthrough oral cancer therapy in Europe for multiple myeloma patients in more than forty years. Multiple myeloma is the second most commonly diagnosed blood cancer. According to the International Myeloma Foundation, there are an estimated 750,000 people with multiple myeloma...
Source: Blood Weekly (2007-07-05)
|
